title: Reply to: Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact.
authors: Global Development, Novartis Vaccines and Diagnostics, Inc., 350 Massachusetts Avenue, Cambridge, MA, USA.
authors: James
authors: J
authors: Wassil
authors: Global Public Health and Market Access, Novartis Vaccines and Diagnostics A.G., Basel, Switzerland.
authors: Jasper
authors: J
authors: Huels
authors: Global Development, Novartis Vaccines and Diagnostics, Inc., 350 Massachusetts Avenue, Cambridge, MA, USA. Electronic address: vas.narasimhan@novartis.com.
authors: Vasant
authors: V
authors: Narasimhan
mesh_terms: D006801:Humans; D008297:Male; D008589:Meningococcal Infections / Q000191:economics* / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000191:economics*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*
chemical_list: D022401:Meningococcal Vaccines